Characterizing the Strength of Evidence in FDA Labels for Pharmacogenomic Biomarker-Guided Medication Use

Main|Search|PHGKB

From Genomics & Health Impact Scan Database

This database includes published scientific literature on evidence-based translation of genomic discoveries into improved health care and disease prevention that have a potential impact on population health.

---

• Characterizing the Strength of Evidence in FDA Labels for Pharmacogenomic Biomarker-Guided Medication Use.  
  Chin Lauren et al. AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science 2017 201730-39
• Are evidence standards different for genomic- vs. clinical-based precision medicine? - A quantitative analysis of individualized warfarin therapy.  
  Dhanda Devender S et al. Clinical pharmacology and therapeutics 2017 Feb
• The current state of implementation science in genomic medicine: opportunities for improvement.  
  Roberts Megan C et al. Genetics in medicine : official journal of the American College of Medical Genetics 2017 Jan
• Meta-Analysis of Genes in Commercially Available Nutrigenomic Tests Denotes Lack of Association with Dietary Intake and Nutrient-Related Pathologies.  
  Pavlidis Cristiana et al. Omics : a journal of integrative biology 2015 Sep 19(9) 512-20
• Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine.  
  Zaric Gregory S et al. PharmacoEconomics 2016 Feb

more